Novagali Pharma

Novagali Pharma was a French biopharmaceutical company specialized in the development and commercialization of innovative ophthalmic products for both the anterior and posterior segments of the eye. The company's core strength lay in its proprietary drug delivery platforms, most notably Novasorb, a cationic emulsion technology that enhances the bioavailability and residence time of medications on the ocular surface. Its lead commercial product, Cationorm, is a preservative-free cationic emulsion for the treatment of dry eye symptoms. Novagali was acquired by Santen Pharmaceutical in 2011, serving as a strategic hub for Santen's expansion into the European market and the integration of advanced ocular drug delivery technologies.